Can B Corp. Announces Holding Company Reorganization With Nascent Pharma Holdings, Inc. to Become the Publicly-Traded Parent Company
Can B Corp (OTCQB: CANB) has implemented a reorganization making Nascent Pharma Holdings, Inc. its new publicly-traded parent company. Existing CANB shares will convert one-for-one into Nascent Pharma Holdings shares. The company's current board and executives will maintain their roles. This reorganization follows Can B's March 2024 strategic shift to focus on protecting and commercializing cannabis patents acquired through its 67%-owned subsidiary, Nascent Pharma, The company expects this restructuring to improve its capital-raising capabilities for future business opportunities, partnerships, licensing agreements, and patent protection efforts.
Can B Corp (OTCQB: CANB) ha attuato una riorganizzazione rendendo Nascent Pharma Holdings, Inc. la sua nuova società madre quotata in borsa. Le azioni esistenti di CANB verranno convertite in un rapporto uno a uno in azioni di Nascent Pharma Holdings. L'attuale consiglio di amministrazione e i dirigenti dell'azienda manterranno i loro ruoli. Questa riorganizzazione segue il cambiamento strategico di Can B di marzo 2024, che mira a concentrarsi sulla protezione e commercializzazione dei brevetti cannabis acquisiti tramite la sua controllata al 67%, Nascent Pharma. L'azienda prevede che questa ristrutturazione migliori le sue capacità di raccolta di capitali per future opportunità commerciali, partnership, accordi di licenza e sforzi di protezione dei brevetti.
Can B Corp (OTCQB: CANB) ha implementado una reorganización haciendo de Nascent Pharma Holdings, Inc. su nueva empresa matriz cotizada en bolsa. Las acciones existentes de CANB se convertirán en una por una en acciones de Nascent Pharma Holdings. La junta actual de la empresa y los ejecutivos mantendrán sus funciones. Esta reorganización sigue al cambio estratégico de Can B de marzo de 2024, que se centra en proteger y comercializar las patentes de cannabis adquiridas a través de su subsidiaria al 67%, Nascent Pharma. La empresa espera que esta reestructuración mejore sus capacidades para recaudar capital para oportunidades comerciales futuras, asociaciones, acuerdos de licencia y esfuerzos de protección de patentes.
Can B Corp (OTCQB: CANB)는 Nascent Pharma Holdings, Inc.를 새로 공개 상장된 모회사를 만들기 위해 재편성을 시행했습니다. 기존의 CANB 주식은 Nascent Pharma Holdings 주식으로 1대1 변환됩니다. 회사의 현재 이사회와 경영진은 그들의 역할을 유지할 것입니다. 이 재편성은 Can B의 2024년 3월 전략적 전환을 따라, 67% 소유 자회사인 Nascent Pharma를 통해 확보한 대마초 특허를 보호하고 상용화하는 데 집중하고자 합니다. 회사는 이번 재구성을 통해 향후 사업 기회, 파트너십, 라이선스 계약 및 특허 보호 노력을 위한 자본 조달 능력이 향상될 것으로 기대하고 있습니다.
Can B Corp (OTCQB: CANB) a mis en œuvre une réorganisation en faisant de Nascent Pharma Holdings, Inc. sa nouvelle société mère cotée en bourse. Les actions existantes de CANB seront converties dans un rapport de un pour un en actions de Nascent Pharma Holdings. Le conseil d'administration actuel et les dirigeants de l'entreprise conserveront leurs rôles. Cette réorganisation fait suite au changement stratégique de Can B en mars 2024, qui vise à se concentrer sur la protection et la commercialisation des brevets de cannabis acquis par l'intermédiaire de sa filiale détenue à 67 %, Nascent Pharma. L'entreprise s'attend à ce que cette restructuration améliore ses capacités de levée de fonds pour les futures opportunités commerciales, les partenariats, les accords de licence et les efforts de protection des brevets.
Can B Corp (OTCQB: CANB) hat eine Neuorganisation umgesetzt, die Nascent Pharma Holdings, Inc. zu ihrem neuen börsennotierten Mutterunternehmen macht. Bestehende CANB-Aktien werden im Verhältnis eins zu eins in Aktien von Nascent Pharma Holdings umgewandelt. Der derzeitige Vorstand und die Führungskräfte des Unternehmens werden ihre Funktionen beibehalten. Diese Neuorganisation folgt auf den strategischen Wandel von Can B im März 2024, der sich darauf konzentriert, Cannabis-Patente zu schützen und zu vermarkten, die über ihre 67%-Tochtergesellschaft, Nascent Pharma, erworben wurden. Das Unternehmen erwartet, dass diese Umstrukturierung seine Fähigkeiten zur Kapitalbeschaffung für zukünftige Geschäftsmöglichkeiten, Partnerschaften, Lizenzvereinbarungen und Patentschutzmaßnahmen verbessern wird.
- Strategic reorganization to enhance capital raising capabilities
- One-for-one share conversion protecting existing shareholders
- 67% ownership in Nascent Pharma with valuable cannabis patents
- Potential costs associated with patent protection litigation
- Uncertainty during trading symbol transition period
Primary Focus on Protecting and Commercializing Cannabis Patents
HICKSVILLE, N.Y., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Can B Corp. (OTCQB: CANB) (“Can B” or the “Company”) today announced that it has implemented a reorganization in which a new holding company, Nascent Pharma Holdings, Inc., has become the publicly-traded parent of Can B and its subsidiaries. As a result of the reorganization, existing shares of Can B stock have been automatically converted, on a one-for-one basis, into shares of common stock of Nascent Pharma Holdings, Inc. The Board and executive officers of Can B will continue in the same roles at Nascent Pharma Holdings, Inc.
In March 2024, Can B announced that it had shifted its primary focus to protecting and commercializing the cannabis patents acquired by its
The change in the name of the publicly traded name and the issuance of a new trading symbol is currently being processed by FINRA. Shares of the publicly traded company will continue to trade under the symbol “CANB” until the processing of the name change is complete and the new trading symbol is issued.
For more information about Nascent Pharma Holdings, Inc., please visit: https://nascentpharmaholdings.com.
About Can B Corp.
Can B Corp. (OTCQB: CANB), through Nascent Pharma Holdings, Inc., is a forward-thinking pharmaceutical Intellectual Property (IP) company, focused on maximizing the value of our cannabis patent portfolios. We own two issued patents registered with the US Patent and Trademark Office (USPTO) covering cannabis extracts and methods of preparation, emphasizing both composition and use.
Forward-Looking Statements
Forward-looking statements and risks and uncertainties discussed in this release contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of latest information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.
Investors and Media:
IR@canbiola.com
(917) 658-7878
FAQ
What is the conversion ratio for Can B Corp (CANB) shares in the Nascent Pharma Holdings reorganization?
Will CANB stock symbol change after the Nascent Pharma Holdings reorganization?
What is Nascent Pharma Holdings' main business focus after the 2024 reorganization?
